04:38 PM IST
EXPLAINED! Anil Singhvi on his campaign to protect investors and save their hard-earned money; reveals market strategy going forward
Good news amid coronavirus! India to emerge as fastest growing G20 economy - Here is how
Cost of coronavirus lockdown: Covid 19 fight will come at high economic cost, beat 2008 crisis, say analysts
Is Indian economy better prepared to deal with COVID-19 than it was during 2008 Global Financial Crisis?
What do RBI announcements mean for common man, Indian economy amid coronavirus lockdownShares of biotechnology firm
Biocon today surged over 7 per cent after the company said it
has received an EIR from the USFDA on closure of inspection of
its aseptic drug product facility.
The stock soared 7.27 per cent to settle at Rs 423 on
BSE. During the day, it zoomed 7.74 per cent to Rs 424.90 -
its 52-week high.
At NSE, shares of the company gained 7.31 per cent to end
at Rs 423.20.
In terms of equity volume, 7.55 lakh shares of the
company were traded on BSE and over 80 lakh shares changed
hands at NSE during the day.
Biocon today said it has received the EIR (Establishment
Inspection Report) with 'voluntary action indicated' status
from the USFDA on closure of inspection of its aseptic drug
product facility.
"The US Food and Drug Administration (USFDA) has issued
an EIR in relation to the cGMP (current good manufacturing
practice) inspection of its aseptic drug product facility that
was audited between May 25 -June 3, 2017," Biocon said in a
BSE filing.
The USFDA releases a copy of EIR to the establishment
that is the subject of an FDA or FDA-contracted inspection
when the agency determines the inspection to be closed.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
